This multicenter study found that intercalating and maintenance use of gefitinib significantly prolonged PFS and OS of selected group of patients with advanced NSCLC and unknown EGFR status who had achieved SD on chemotherapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.